Novogen Limited (KZIA) – What Are Researchers Thinking About This Stock?

Shares of Novogen Limited (NASDAQ:KZIA) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $29.50.

A number of analysts have weighed in on the company. Guggenheim assumed coverage on Novogen in a report on Wednesday, October 21st. They set a “buy” rating and a $35.00 price target for the company. Needham & Company LLC initiated coverage on Novogen in a research report on Friday, October 30th. They set a “buy” rating and a $27.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research report on Thursday, October 15th. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Novogen in a research note on Thursday, September 10th. Finally, Leerink Partners assumed coverage on Novogen in a report on Tuesday, October 20th. They issued an “outperform” rating and a $30.00 target price for the company.

Novogen Stock Performance

KZIA stock opened at $7.18 on Friday. The company’s fifty day simple moving average is $9.56 and its 200 day simple moving average is $10.50. Novogen has a 12-month low of $4.86 and a 12-month high of $17.40.

Novogen Company Profile

Novogen Limited was an Australian biotechnology company that developed novel therapies for cancer. The company focused on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival, with an emphasis on cancers that have limited treatment options.

In 2016, Novogen changed its name to Kazia Therapeutics Limited and continued its oncology research under the Kazia name. Its principal development program became paxalisib, an investigational PI3K/mTOR inhibitor being studied for brain cancers, including glioblastoma and brain metastases.